Second Sight Medical Products (NASDAQ: EYES) is one of 19 public companies in the “Medical Devices & Implants” industry, but how does it contrast to its competitors? We will compare Second Sight Medical Products to similar companies based on the strength of its valuation, analyst recommendations, institutional ownership, earnings, risk, dividends and profitability.
This table compares Second Sight Medical Products and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Second Sight Medical Products||-565.12%||-184.87%||-137.77%|
|Second Sight Medical Products Competitors||-101.23%||-92.70%||-30.32%|
This is a breakdown of current ratings and target prices for Second Sight Medical Products and its competitors, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Second Sight Medical Products||0||0||1||0||3.00|
|Second Sight Medical Products Competitors||111||728||1026||10||2.50|
Second Sight Medical Products presently has a consensus price target of $5.00, suggesting a potential upside of 199.40%. As a group, “Medical Devices & Implants” companies have a potential upside of 36.43%. Given Second Sight Medical Products’ stronger consensus rating and higher probable upside, analysts plainly believe Second Sight Medical Products is more favorable than its competitors.
Institutional and Insider Ownership
12.8% of Second Sight Medical Products shares are owned by institutional investors. Comparatively, 54.8% of shares of all “Medical Devices & Implants” companies are owned by institutional investors. 34.7% of Second Sight Medical Products shares are owned by insiders. Comparatively, 10.3% of shares of all “Medical Devices & Implants” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Valuation & Earnings
This table compares Second Sight Medical Products and its competitors revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Second Sight Medical Products||$3.98 million||-$33.17 million||-2.61|
|Second Sight Medical Products Competitors||$1.67 billion||$207.58 million||86.85|
Second Sight Medical Products’ competitors have higher revenue and earnings than Second Sight Medical Products. Second Sight Medical Products is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
Volatility and Risk
Second Sight Medical Products has a beta of 3.67, suggesting that its stock price is 267% more volatile than the S&P 500. Comparatively, Second Sight Medical Products’ competitors have a beta of 0.47, suggesting that their average stock price is 53% less volatile than the S&P 500.
Second Sight Medical Products competitors beat Second Sight Medical Products on 7 of the 12 factors compared.
About Second Sight Medical Products
Second Sight Medical Products, Inc. is engaged in developing, manufacturing and marketing prosthetic devices that restore vision to blind individuals. The Company’s product, the Argus II System, treats outer retinal degenerations, such as retinitis pigmentosa (RP). The Argus II System provides an artificial form of vision that differs from the vision of people with normal sight. It does not restore normal vision and it does not slow or reverse the progression of the disease. The Company’s Argus II System employs electrical stimulation to bypass degenerated photoreceptor cells and to stimulate remaining viable retinal cells thereby inducing visual perception in blind individuals. The Argus II System works by converting video images captured by a miniature camera housed in a patient’s glasses into a series of small electrical pulses that are transmitted wirelessly to an array of electrodes that are implanted on the surface of the retina.
What are top analysts saying about Second Sight Medical Products Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Second Sight Medical Products Inc. and related companies.